Marker Therapeutics, Inc.
MRKR
$1.19
$0.00030.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.59M | 5.40M | 3.73M | 3.32M | 3.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.59M | 5.40M | 3.73M | 3.32M | 3.31M |
| Cost of Revenue | 13.47M | 11.00M | 9.57M | 9.62M | 10.42M |
| Gross Profit | -6.88M | -5.60M | -5.85M | -6.29M | -7.11M |
| SG&A Expenses | 4.24M | 4.59M | 5.15M | 6.53M | 7.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.71M | 15.59M | 14.72M | 16.14M | 17.89M |
| Operating Income | -11.12M | -10.19M | -10.99M | -12.82M | -14.58M |
| Income Before Tax | -10.68M | -9.63M | -10.30M | -12.21M | -14.04M |
| Income Tax Expenses | 50.00K | 3.70K | 3.70K | 3.70K | 3.70K |
| Earnings from Continuing Operations | -10.73 | -9.63 | -10.31 | -12.21 | -14.05 |
| Earnings from Discontinued Operations | -- | -62.90K | -62.90K | 6.55M | 5.81M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.73M | -9.70M | -10.37M | -5.66M | -8.24M |
| EBIT | -11.12M | -10.19M | -10.99M | -12.82M | -14.58M |
| EBITDA | -- | -2.24M | -4.74M | -8.06M | -11.55M |
| EPS Basic | -1.19 | -1.09 | -1.17 | -0.64 | -0.94 |
| Normalized Basic EPS | -0.74 | -0.68 | -0.73 | -0.86 | -1.00 |
| EPS Diluted | -1.20 | -1.10 | -1.18 | -0.64 | -0.94 |
| Normalized Diluted EPS | -0.74 | -0.68 | -0.73 | -0.86 | -1.00 |
| Average Basic Shares Outstanding | 35.92M | 35.63M | 35.54M | 35.42M | 35.24M |
| Average Diluted Shares Outstanding | 35.92M | 35.63M | 35.54M | 35.42M | 35.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |